Oncotarget

Research Papers:

Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways

Tai Yang _, Jin Liu, Mali Yang, Ning Huang, Yueling Zhong, Ting Zeng, Rong Wei, Zhongjun Wu, Cui Xiao, Xiaohua Cao, Minhui Li, Limei Li, Bin Han, Xiaoping Yu, Hua Li, Qiang Zou

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:5800-5813. https://doi.org/10.18632/oncotarget.10584

Metrics: PDF 535 views  |   HTML 705 views  |   ?  


Abstract

Tai Yang1,2,*, Jin Liu2,*, Mali Yang2,*, Ning Huang3, Yueling Zhong1, Ting Zeng2, Rong Wei2, Zhongjun Wu2, Cui Xiao2, Xiaohua Cao2, Minhui Li2, Limei Li2, Bin Han4, Xiaoping Yu4, Hua Li5, Qiang Zou2

1School of Pharmacy, Chengdu Medical College, Chengdu, China

2Department of Immunology, Chengdu Medical College, Chengdu, China

3Laboratory for Aging Research, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China

4Department of Public Health, Chengdu Medical College, Chengdu, China

5Cancer Center, Chengdu Military General Hospital, Chengdu, China

*These authors have contributed equally to this work

Correspondence to:

Tai Yang, email: yangtai.bio@qq.com

Qiang Zou, email: qiangzou99@gmail.com

Keywords: cucurbitacin B, multiple myeloma, Aurora A kinase, multiple cellular pathways, xenograft

Received: March 07, 2016     Accepted: June 30, 2016     Published: July 13, 2016

ABSTRACT

Cucurbitacin B (CuB), a triterpenoid compound isolated from the stems of Cucumis melo, has long been used to treat hepatitis and hepatoma in China. Although its remarkable anti-cancer activities have been reported, the mechanism by which it achieves this therapeutic activity remains unclear. This study was designed to investigate the molecular mechanisms by which CuB inhibits cancer cell proliferation. Our results indicate that CuB is a novel inhibitor of Aurora A in multiple myeloma (MM) cells, arresting cells in the G2/M phase. CuB also inhibited IL-10-induced STAT3 phosphorylation, synergistically increasing the anti-tumor activity of Adriamycin in vitro. CuB induced dephosphorylation of cofilin, resulting in the loss of mitochondrial membrane potential, release of cytochrome c, and activation of caspase-8. CuB inhibited MM tumor growth in a murine MM model, without host toxicity. In conclusion, these results indicate that CuB interferes with multiple cellular pathways in MM cells. CuB thus represents a promising therapeutic tool for the treatment of MM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10584